Results 111 to 120 of about 41,093 (223)

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. [PDF]

, 2006
OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area.
Lowe, B, Bejon, P, Hill, Adrian, Gilbert, Sarah, Lang Trudie, Lang, T, Peshu, N, Lowe, Brett, Molyneux, C, Fegan Greg, Hill, AV, Milligan Paul, Hill Adrian V. S, Gilbert, Sarah C, Bejon, Philip, Marsh Kevin, Mwacharo Jedidah, Mwangi, T, Mwangi, Tabitha, Fegan, G, Todryk, S, Molyneux, Catherine, Keating, S, Kai, Oscar, Lang, Trudie, Gilbert, SC, Mwacharo, J, Gikonyo, C, Molyneux Catherine, Kai, O, Gilbert Sarah C, Keating, Sheila, Mwangi Tabitha, Todryk, Stephen, Hill, Adrian VS, Kai Oscar, Greg Fegan, Mwacharo, Jedidah, Peshu, Norbert, Todryk Stephen, Milligan, Paul, Marsh, K, Peshu Norbert, Lowe Brett, Gikonyo, Caroline, Bejon Philip, Fegan, Greg, Milligan, P, Keating Sheila, Marsh, Kevin, Gikonyo Caroline   +50 more
core   +1 more source

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

Advanced Science, Volume 13, Issue 37, 3 July 2026.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel, Anna‐Sophie Schlemmer, Andrea W. Eiken, Zachary W. Wagoner, Dennis Vöhringer, Lena Christ, Alex Dulovic, Patrick Marsall, Madeleine Fandrich, Eduardo J. S. Brás, Julia Marzi, Friederike Bärhold, Julia Philipp, Sven Becker, Lisa E. Wagar, Peter Loskill   +15 more
wiley   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca, Abdulla, Salim, Tanner, M., Schellenberg David, Vekemans, J., Richard Kamata, Kamata, Richard, Grace Mwangoka, Kubhoja, S., Leach, Amanda, Villafana Tonya, Dubois Marie-Claude, Sulende Kubhoja, Carter, T, Carter Terrell, Villafana, T, Dubois, M-C, Salim Nahya, Mshinda, H, Dubois, Marie-Claude, Leach, A, Joe Cohen, Salim, N, Kubhoja, Sulende, Vekemans Johan, Salim Abdulla, Mwangoka, G, Carter, T., Juma, O., Mohammed, A., Marcel Tanner, Marie-Claude Dubois, Mshinda Hassan, Marc Lievens, Aebi, Thomas, Kamata, R., Nahya Salim, Ballou, W Ripley, Machera, F., Leach, A., Lievens, Marc, Mohammed Ali, Leach Amanda, Ballou, W. R., W Ripley Ballou, Abdulla, S, Amanda Leach, Kubhoja Sulende, Cohen Joe, Ali Mohammed, Mwangoka Grace, Lievens Marc, Salim, N., Cohen, J., Hassan Mshinda, Abdulla, S., Mohammed, A, Aebi, T, Shomari, M, Mwangoka, G., Schellenberg, D, Cohen, Joe, Schellenberg, D., Machera Francisca, Tanner Marcel, Abdulla Salim, Tanner, M, Carter, Terrell, Juma, Omar, Ballou W Ripley, Omar Juma, Machera, F, Shomari, Mwanajaa, Aebi, T., Schellenberg, David, Mwanajaa Shomari, Lievens, M, Cohen, J, Thomas Aebi, Lievens, M., Juma Omar, Vekemans, J, Juma, O, Vekemans, Johan, Mshinda, Hassan, Tanner, Marcel, Shomari Mwanajaa, Mwangoka, Grace, David Schellenberg, Francisca Machera, Villafana, T., Shomari, M., Mshinda, H., Terrell Carter, Salim, Nahya, Mohammed, Ali, Dubois, M. C., Ballou, WR, Tonya Villafana, Kamata Richard, Kubhoja, S, Aebi Thomas, Johan Vekemans, Kamata, R, Villafana, Tonya   +104 more
core   +1 more source

Targeting mucosal immunity in malaria control: the underexplored role of IgA

Frontiers in Malaria
Malaria remains a global health crisis, causing an estimated 263 million cases and 597,000 deaths in 2023. Current measures—including insecticide-treated nets, ACTs, and the RTS,S vaccine—have stalled in reducing mortality, highlighting the need for ...
Haruna Muwonge, Haruna Muwonge, Isaac Ssewanyana, Adoke Yeka, Pauline Byakika-Kibwika, Pauline Byakika-Kibwika   +5 more
doaj   +1 more source

An Open‐Source Systematic Reviews Integrated System (OSSYRIS) – Streamlining Processes and Standardising Data Structures

Cochrane Evidence Synthesis and Methods, Volume 4, Issue 4, July 2026.
ABSTRACT Introduction Carrying out a systematic review (SR) of the literature entails a high workload and encompasses a variety of very different tasks. The emergence of artificial intelligence tools has brought further opportunities to improve the efficiency and reliability of SRs.
Xavier Bosch‐Capblanch, Christian Auer, A. S. M. Sayem, Guillaume Deschamps, Salvador Camacho, Luís Segura, Salem Al‐Aidroos, George Tsey Sabblah, Kaspar Wyss   +8 more
wiley   +1 more source

Malaria transmission-blocking vaccines—how can their development be supported? [PDF]

, 2000
Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of ...
Louis Molineaux, Carter, Richard, Molineaux, Louis, Mendis, Kamini N, Saul, Allan, Allan Saul, Richard Carter, Miller, Louis H, Louis H. Miller, Kamini N. Mendis   +9 more
core   +1 more source

Domestic and International Health Expenditure and Health and Healthcare Use: Evidence From Mozambique

Health Economics, Volume 35, Issue 7, Page 1088-1103, July 2026.
ABSTRACT Evidence on the relationship between public health expenditure and health is mixed and particularly scarce for low‐income countries. Existing studies overlook the subnational distribution of expenditure and rarely distinguish between sources and governance over funding.
Eliana Chavarría‐Pino, Laura Anselmi, Matt Sutton, Sérgio Chicumbe   +3 more
wiley   +1 more source

Paths to a malaria vaccine illuminated by parasite genomics. [PDF]

, 2015
More human death and disease is caused by malaria parasites than by all other eukaryotic pathogens combined. As early as the sequencing of the first human genome, malaria parasite genomics was prioritized to fuel the discovery of vaccine candidate ...
Conway, David J, Conway, David J.
core   +1 more source

Identification of SNPs Associated With mRNA Expression Differences of the Complement Receptor Type 1‐Like Gene in Landrace Weaned Piglets

Veterinary Medicine and Science, Volume 12, Issue 4, July 2026.
ABSTRACT Objective The aim of this study is to investigate the association between single nucleotide polymorphisms (SNPs) of porcine complement receptor 1‐like (CR1‐like) gene and its mRNA expression. Methods SNP identification, qRT‐PCR absolute quantification, linkage disequilibrium analysis and dual‐luciferase reporter assay were performed using 392 ...
Wei Yin, Jiachen Cheng, Qiongyu Li, Luyang Xu, Hongquan Li, Kuohai Fan, Zhenbiao Zhang, Na Sun, Panpan Sun, Huizhen Yang   +9 more
wiley   +1 more source

Creating Markets for New Vaccines Part I: Rationale [PDF]

Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to ...
Michael Kremer
core